
Acceleron Pharma
- Employees: 130
- Market Cap: $1.51 billion
- Revenue: $13.24 million
- 5 Year Trend: 2.4%
- Net Income: $-91.32 million
- NASDAQ: XLRN
Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Boston, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-ß) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels. John Knopf, Jasbir Seehra, Tom Maniatis, Mark Ptashne and Wylie Vale formed the company in Cambridge, Massachusetts. Wikipedia
Acceleron Pharma
Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Boston, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-ß) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels. John Knopf, Jasbir Seehra, Tom Maniatis, Mark Ptashne and Wylie Vale formed the company in Cambridge, Massachusetts. Wikipedia

- Employees: 130
- Market Cap: $1.51 billion
- Revenue: $13.24 million
- 5 Year Trend: 2.4%
- Net Income: $-91.32 million
- NASDAQ: XLRN